Juan Carlos Hernández Boluda-rekin lankidetzan egindako argitalpenak (19)

2024

  1. Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease

    Bone Marrow Transplantation, Vol. 59, Núm. 8, pp. 1118-1126

  2. Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis

    Bone Marrow Transplantation

  3. Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy

    Infection

  4. Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy

    Bone Marrow Transplantation, Vol. 59, Núm. 1, pp. 93-100

2023

  1. Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study

    Journal of medical virology, Vol. 95, Núm. 7, pp. e28933

  2. Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?

    Clinical Microbiology and Infection

  3. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir

    Transplant Infectious Disease, Vol. 25, Núm. 2

  4. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

    British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61

  5. Impact of cytomegalovirus immunodominant HLA-I donor–recipient matching on the incidence and features of virus DNAemia and virus-specific T-cell immune reconstitution in unmanipulated haploidentical hematopoietic stem cell transplantation

    Transplant Infectious Disease, Vol. 25, Núm. 3

2022

  1. Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients

    BMC Infectious Diseases, Vol. 22, Núm. 1

  2. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

    Journal of hematology & oncology, Vol. 15, Núm. 1, pp. 54

2021

  1. An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation

    Journal of Medical Virology, Vol. 93, Núm. 8, pp. 4773-4779

  2. Diversity and dynamic changes of anelloviruses in plasma following allogeneic hematopoietic stem cell transplantation

    Journal of Medical Virology, Vol. 93, Núm. 8, pp. 5167-5172

  3. Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation

    Transplant Infectious Disease, Vol. 23, Núm. 3

2020

  1. Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation

    Transplant Infectious Disease, Vol. 22, Núm. 4

  2. Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?

    Transplant Infectious Disease, Vol. 22, Núm. 6

  3. Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide

    Bone Marrow Transplantation

  4. Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide

    Bone Marrow Transplantation, Vol. 55, Núm. 7, pp. 1347-1356

  5. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors

    Bone Marrow Transplantation, Vol. 55, Núm. 11, pp. 2147-2159